Daiichi Sankyo’s H1 Sales Jump 19.5% on Robust Global Products

Daiichi Sankyo said on October 31 that its first-half revenue grew 19.5% year over year, spurred by growth of major global products Enhertu (trastuzumab deruxtecan) and Lixiana (edoxaban) as well as a currency tailwind. In April-September, the Japanese pharma major...read more